Biotechnology - Biotechnology, CSL Limited

Filter

Current filters:

BiotechnologyCSL Limited

Popular Filters

CSL opens Australian biotechnology manufacturing facility

09-05-2014

Leading Australian biotech firm CSL Limited has opened the CSL Behring Biotechnology manufacturing facility…

AustraliaBiotechnologyCSL BehringCSL LimitedHematologyProductionResearch

US FDA clears Biogen Idec and SOBI’s Alprolix for hemophilia B

US FDA clears Biogen Idec and SOBI’s Alprolix for hemophilia B

31-03-2014

Marking a second regulatory hurdle for the breakthrough product, the US Food and Drug Administration…

AlprolixBenefixBiogen IdecBiotechnologyCSL LimitedHematologyNorth AmericaNovo NordiskPfizerRegulationSwedish Orphan BiovitrumUSA

Report: IPOs and government support can boost the Australian life sciences industry

Report: IPOs and government support can boost the Australian life sciences industry

18-02-2014

Despite a relatively flat December quarter for the PricewaterhouseCoopers Life Sciences Index, it was…

AustraliaBiotechnologyCSL LimitedFinancialMarkets & MarketingPharmaceutical

Janssen in-licenses rights to novel cancer therapy from CSL

Janssen in-licenses rights to novel cancer therapy from CSL

05-12-2013

Australian blood products and vaccine maker CSL Ltd has entered into an agreement with Janssen Biotech,…

BiotechnologyCSL LimitedHematologyImmunologicalsJanssen BiotechJohnson & JohnsonLicensingOncology

FDA approves CSL's Kcentra and accepts Octapharma Octaplex BLA for reversal of anticoagulation

30-04-2013

The US Food and Drug Administration has approved Kcentra (prothrombin complex concentrate, human) from…

BiotechnologyCardio-vascularCSL BehringCSL LimitedKcentraNorth AmericaOctapharmaOctaplexPharmaceuticalRegulation

CSL Behring's Berinert OKed in Europe for short-term prophylaxis in HAE

16-04-2013

Germany-based CSL Behring, a unit of Australia's CSL Ltd (ASX: CSL) says that European health authorities…

BerinertBiotechnologyCSL BehringCSL LimitedEuropeRare diseasesRegulation

CSL Behring enrolls first patient in pediatric Ph III pivotal study of rIX-FP to treat hemophilia B

21-01-2013

USA-based CSL Behring, a subsidiary of Australia's CSL Ltd (ASX: CSL) has announced that the first patient…

BiotechnologyCSL BehringCSL LimitedResearchriX-FP

CSL Biotherapies indentifies likely reason for Fluvax problems

21-06-2012

Australia's largest biotech firm CSL Biotherapies, a division of CSL Limited (ASX: CSL) today presented…

Asia-PacificBiotechnologyCSL BiotherapiesCSL LimitedFluvaxMarkets & MarketingVaccines

Back to top